Skip to main content

Table 4 The effect of Matrix Model treatment, MPH and matrix-methylphenidate on clinical parameters in METH users 1

From: The therapeutic effects of methylphenidate and matrix-methylphenidate on addiction severity, craving, relapse and mental health in the methamphetamine use disorder

Group
Variable
Matrix (n = 20) Methylphenidate (n = 22) Matrix combination with methylphenidate (n = 21) Control (n = 22) P-value* Effect size
DDQ2 Baseline 53.4 ± 6.4 53.9 ± 4.8 54.9 ± 4.5 55.9 ± 4.5 < 0.001 0.387
 End-of-trial 53.7 ± 5.7a 51.2 ± 4.0 49.4 ± 5.5 56.4 ± 3.7b
P-value** 0.701 < 0.001 < 0.001 0.291   
LDQ3 Baseline 21.2 ± 2.8 20.6 ± 2.6 22.3 ± 2.9 20.8 ± 2.8 < 0.001 0.226
 End-of-trial 21.9 ± 2.9a 19.5 ± 2.3 19.3 ± 1.4 20.2 ± 1.6
P-value** 0.410 0.004 < 0.001 0.304   
GHQ4 Baseline 31.4 ± 4.9 28.2 ± 6.6 30.9 ± 4.8 31.4 ± 5.3 0.001 0.178
 End-of-trial 30.3 ± 4.2 27.6 ± 5.2 27.0 ± 5.0c 30.6 ± 5.5
P-value** 0.096 0.480 < 0.001 0.195   
  1. 1 Data are mean ± SDs
  2. 2 DDQ: Desire for Drug Questionnaire
  3. 3 LDQ: Leeds Dependence Questionnaire
  4. 4 GHQ: General Health Questionnaire
  5. a: Significant difference between Matrix with Methylphenidate and Matrix combination with methylphenidate groups (Bonferroni test)
  6. b: Significant difference between Control with Methylphenidate and Matrix combination with methylphenidate groups (Bonferroni test)
  7. c: Significant difference between Matrix combination with methylphenidate with other groups (Bonferroni test)
  8. * ANCOVA test/ ** Paired t-test